Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer by Wapnir, Irene L et al.
Progress on BIG 1-02/IBCSG 27-02/NSABP B-37,
a Prospective Randomized Trial Evaluating Chemotherapy
after Local Therapy for Isolated Locoregional Recurrences
of Breast Cancer
Irene L. Wapnir, MD,1,2 Stefan Aebi, MD,3 Shari Gelber, MS,4,5 Stewart J. Anderson,
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Background: The utility of chemotherapy for women who experience a locoregional
recurrence after primary treatment of early breast cancer remains an open question. An
international collaborative trial is being conducted by the Breast International Group (BIG),
the International Breast Cancer Study Group (IBCSG), and the National Surgical Adjuvant
Breast and Bowel Project (NSABP) to determine the effectiveness of cytotoxic therapy for
these patients, either alone or in addition to selective use of hormonal therapy and trast-
uzumab.
Methods: The trial population includes women who have had a previous diagnosis of
invasive breast cancer treated by mastectomy or breast-conserving surgery, but subsequently
develop an isolated local and/or regional ipsilateral invasive recurrence. Excision of all mac-
roscopic tumor without evidence of systemic disease is required for study entry. Patients are
randomized to receive chemotherapy or no chemotherapy; type of chemotherapy is not pro-
tocol-specified. Radiation, hormonal therapy, and trastuzumab are given as appropriate. The
primary endpoint is disease-free survival (DFS). Quality-of-life measurements are collected at
baseline, and then at 9 and 12 months. The accrual goal is 977 patients.
Results: This report describes the characteristics of the first 99 patients. Sites of recurrence
at study entry were: breast (56%), mastectomy scar/chest wall (35%), and regional lymph
nodes (9%). Two-thirds of patients have estrogen-receptor-positive recurrences.
Conclusion: This is the only trial actively investigating the question of ‘‘adjuvant’’ chemo-
therapy in locally recurrent breast cancer. The case mix of accrual to date indicates a broad
representation of this patient population.
The risk of developing metastatic disease is in-
creased among women who develop isolated locore-
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gional recurrences following treatment of primary
breast cancer.1 Stage of the index cancer, use of prior
adjuvant therapy, and time to recurrence may mod-
ulate the prognosis of this patient population.2–9
Published series report less than 50% 5-year survival
in patients experiencing post-mastectomy recurrences
and 39–84% 5-year survival in women experiencing
ipsilateral breast tumor recurrences after breast-con-
serving therapy.2–6,9–19 In a cross-protocol analysis of
five National Surgical Adjuvant Breast and Bowel
Project (NSABP) node-positive prospective random-
ized trials, 5-year disease-free survival (DFS) and
overall survival (OS) following ipsilateral breast tu-
mor recurrence (IBTR) were 51.4% and 59.9%,
respectively.9 In contrast, patients with other locore-
gional recurrences (oLRR), excluding IBTRs, fared
considerably worse, with 5-year survival of 24.1%.
Three small prospective randomized clinical trials
have attempted to test the effectiveness of systemic
therapy in patients with locally recurrent breast
cancer.20–22 The Swiss Group for Clinical Cancer
Research (SAKK) trial was able to randomize only
50 women with such high-risk tumors to observation
versus vincristine, doxorubicin, and cyclophospha-
mide and closed the study due to the poor accrual
with no results reported to date.23 In the same SAKK
trial patients with lower-risk estrogen-receptor-posi-
tive (ER+) tumors showed improvement in 5-year
DFS if randomized to tamoxifen after radical exci-
sion of post-mastectomy recurrences and local
radiotherapy of 50 Gy.10
An ongoing international multicenter clinical trial
(BIG 1-02/IBCSG 27-02/NSABP B-37) is attempting
to determine if the substantial risk of systemic re-
lapse following a locoregional recurrence can be
reduced by the administration of chemotherapy ei-
ther alone or in addition to appropriate targeted
systemic therapies such as hormonal therapy and
trastuzumab. The routine use of alkylating agents,
anthracyclines, and/or taxanes as prior adjuvant
therapy as well as selective estrogen-receptor mod-
ulators and aromatase inhibitors mandates flexibility
in the selection of systemic therapies for isolated
locoregional relapse. Although it would have been
conceptually preferable to restrict possible treat-
ments to a few specific regimens, such a design was
impractical given the variety of first-line adjuvant
treatments used internationally for adjuvant therapy
of breast cancer.
Our intent herein is to describe progress on this
clinical trial, to encourage participation, and to in-
crease awareness among surgical oncologists who
routinely care for such patients.
METHODS
Study Design and Patient Entry
The trial (BIG 1-02/IBCSG 27-02/NSABP B-37)
openedwith theBreast InternationalGroup (BIG) and
International Breast Cancer Study Group (IBCSG) in
2002, and became a collaborative effort with the
NSABP in 2005. About half of the patients entered
thus far have come fromNorthAmerican centers. This
study was approved by the appropriate institutional
review committees in accordance with assurances filed
with and approved by the Department of Health and
Human Services. Written informed consent was re-
quired for participation in each trial.
Figure 1 depicts the trial schema. Randomization
to either observation (with or without radiation) or
chemotherapy (with or without radiation) must take
place within 12 weeks of definitive surgical resection
of the locoregional recurrence. Patients are stratified
according to the use of prior chemotherapy, receptor
status [ER- and/or progesterone receptor (PgR)-po-
sitive or both negative, as determined by institutional
guidelines] of the recurrence, and the location of the
recurrence (breast, mastectomy scar/chest wall, or
regional lymph nodes).
The trial is open to patients who have developed a
histologically proven isolated invasive locoregional
recurrence following the treatmentof aprimary invasive
breast cancer.24 Patients can be enrolled by members of
the appropriate groups by accessing the websites of
those groups: IBCSG at http://www.ibcsg.org/public/
general_pages/trial/open/trial_27-02.shtml; NSABP at
http://www.nsabp.pitt.edu/B-37.asp; BIG at http://
www.ibcsg27-02_big1-02@ibcsg.org; and by nonmem-
bers through theClinicalTrialsSupportUnit (CTSU)at
http://www.ctsu.org. Patients must have received either
breast-conserving therapy or mastectomy for the index
cancer and must have had all macroscopic recurrent
disease excised. Specifically, margins must be either
uninvolved (R0) or only microscopically involved (R1)
to meet study selection criteria. Mastectomy or repeat
lumpectomy is allowed for patients who received prior
lumpectomy.
Only women with histologically proven first local
and/or regional recurrence of invasive breast cancer
on the same side as their primary cancer are consid-
ered eligible. Patients may enter the study irrespective
of whether lymph node staging surgery or radiation
therapy was used in the treatment of the primary
breast cancer. Sites of recurrence are defined as: any
soft tissue of the ipsilateral conserved breast or the
chest wall, mastectomy scar, and/or skin. Regional
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failure is defined as a tumor recurrence in the ipsi-
lateral axillary lymph nodes, extranodal soft tissue of
the ipsilateral axilla, and/or ipsilateral internal
mammary nodes. Patients with supraclavicular
lymph node recurrences, recurrences in the opposite
breast, or any evidence of distant disease are not
eligible.
Prior to study entry, written informed consent,
baseline quality-of-life assessment, and stratification
factor information are required. Pathology reports of
the primary tumor and recurrence are required. Non-
North-American institutions are encouraged to store
tumor blocks from both the primary and recurrent
tumors for future pathology studies.
Treatment for Locoregional Recurrence
Chemotherapy, if assigned, should begin within
4 weeks of the date of randomization. The choice of
chemotherapy drugs, dose adjustments, and use of
supportive therapy is left to the discretion of the
investigator, but multidrug chemotherapy regimens
for at least three cycles or 3 to 6 months are sug-
gested. Estrogen receptor downregulators, aromatase
inhibitors, and ovarian suppression are all acceptable
alternatives for the required hormonal therapy for
estrogen receptor positive (ER+) and/or progester-
one positive (PR+) tumors. Adjuvant trastuzumab
therapy is allowed for HER-2 overexpressing tumors
but can only be administered with chemotherapy if
randomized to the chemotherapy arm. Intent to use
trastuzumab therapy must be declared prior to ran-
domization.
When radiotherapy is indicated, a dose equivalent
to ‡40 Gy is required. Radiotherapy can be admin-
istered before, during or after chemotherapy. Patients
who develop an IBTR and are treated with mastec-
tomy are not required to undergo radiation therapy
even if radiotherapy was not a component of the
original breast-conserving therapy. Radiation ther-
apy equivalent to ‡40 Gy is mandatory for all other
patients who have not received radiation. For those
previously irradiated patients, additional radiation is
considered unnecessary if margins of resection are
negative (R0). Additional radiation, such as a small-
volume boost to the high-risk area is required if
margins are microscopically positive. In the latter
case, the radiation field must encompass a safety
margin beyond the positive margin.
Quality-of-Life Study
The quality-of-life study includes a baseline
assessment (before randomization) and assessments
at 9 and 12 months after randomization to allow
treatment comparisons after chemotherapy is com-
pleted. Each assessment includes global linear analog
self-assessment (LASA) indicators for physical well-
being, mood, coping (PACIS), perceived social sup-
port, and subjective health estimation (SHE).25
LASA indicators specific to symptoms of nausea and
vomiting, tiredness, hot flushes, and restrictions in
arm movement are also included.
Data Analyses
The primary analysis will be intent-to-treat and
the calculated study sample size is 977 patients.
Based on previous studies we assume that the
overall 5-year DFS for the group receiving no che-
motherapy will be 50%. A total of 347 events is
required to detect an improvement in 5-year DFS to
60% (hazard ratio 0.74) with 80% power using a
two-sided 0.05 level log-rank test. This accounts for
two interim analyses during the conduct of the
study. To account for nonevaluable cases (5%),
the target accrual should be 977 total patients. The
outcome measures for efficacy comparisons are
DFS, systemic DFS, and OS.
RESULTS
The current report summarizes the clinical–patho-
logical characteristics of the first 99 patients ran-
domized onto BIG 1-02/IBCSG 27-02/NSABP B-37.
At study entry most patients had a local recurrence,
prior chemotherapy, were postmenopausal, and had
hormone-receptor-positive disease (Table 1). The
recurrences occurred in the ipsilateral breast in 56%,
the mastectomy skin/chest wall in 35%, and in re-
gional lymph nodes in 9% (Fig. 2). Sixty-five percent
of patients had received adjuvant chemotherapy.
Recurrent tumors were hormone receptor positive by
institutional standards in 65% of patients. Table 1
FIG. 1. Schema for the BIG 1-02/IBCSG 27-02/NSABP B-37
study. This figure was previously published in a modified form.24
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shows that the patient and tumor characteristics were
balanced according to randomized treatment group.
DISCUSSION
This study represents the last opportunity to for-
mally assess whether chemotherapy adds any benefit
to definitive local therapy and systemic targeted
therapies for resected, isolated locoregional recur-
rence of breast cancer. Accrual to this trial has been
slower than needed to complete the trial. We recog-
nize that, since isolated locoregional recurrences are
infrequent, institutions may have relatively few eli-
gible patients, which can serve as a potential deterrent
to activation of the study.
Additionally, in the absence of randomized clinical
trial data, patients and physicians have developed
biases for or against chemotherapy, which can be a
substantial barrier to the successful conduct of sci-
entifically valid trials. Because nearly half the patients
entered have chest wall or regional nodal recurrences
and over one-third have ER-negative tumors, it is
likely that both high- and low-risk cases are being
accrued, and thus the trial population is representa-
tive of the population at large. BIG 1-02/NSABP
B-37/IBCSG 27-02 is an important final effort aimed
at providing definitive data needed to evolve evi-
dence-based therapeutic guidelines for patients with
isolated invasive recurrences of breast cancer. The
trial can only be completed if surgical and medical
oncologists commit to the importance of answering
the question being addressed and insist the study be
opened and supported in their institution even
though accrual will be challenging.
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TABLE 1. Incidence of patient and disease characteristics at study entry
Observation Chemotherapy Total
Total patients 50 49 99
ER/PgR status
Negative 18 (36%) 17 (35%) 35 (35%)
Positive 32 (64%) 32 (65%) 64 (65%)
Prior chemotherapy
No 18 (36%) 17 (35%) 35 (35%)
Yes 32 (64%) 32 (65%) 65 (65%)
Location of primary recurrence
Breast 27 (54%) 28 (57%) 55 (56%)
Mx scar/chest wall 18 (36%) 17 (35%) 35 (35%)
Regional lymph nodes 5 (10%) 4 (8%) 9 (9%)
Menopausal status
Pre 11 (26%) 10 (27%) 21 (26%)
Post 32 (74%) 27 (73%) 59 (74%)
Not yet available 7 12 19
Tumor size
£2 cm 27 (69%) 24 (67%) 51 (68%)
>2 cm 12 (31%) 12 (33%) 24 (32%)
Not yet available 11 13 24
Age
30–39 years 5 (10%) 3 (6%) 8 (8%)
40–49 years 10 (20%) 11 (22%) 21 (21%)
50–59 years 19 (38%) 22 (45%) 41 (41%)
60–69 years 10 (20%) 12 (24%) 22 (22%)
‡70 years 6 (12%) 1 (2%) 7 (7%)
ER, estrogen receptor; PgR, progesterone receptor.
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FIG. 2. Sites of locoregional recurrences in the first 99 patients.
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